Clinical

An increase in the use of comprehensive genomic profiling among patients with advanced non–small cell lung cancer (NSCLC) was associated with additional life-years gained and a low-cost budget impact.

A new review explored using partial tandem duplication levels from the MLL gene to monitor for minimal residual disease (MRD) status to predict disease relapse following allogeneic hematopoietic stem cell transplant.

New research identified risk factors for postoperative migraine and compared the incidence of migraine following general or neuraxial anesthesia.

Pfizer’s COVID-19 vaccine booster can be safely administered alongside a pneumonia vaccine; 3.5 million cancer deaths were prevented in recent decades, but disparities persist; the FDA warns of dental problems linked to a drug to treat opioid use disorder.

While acute lymphoblastic leukemia (ALL) was still the primary cause of death, researchers saw a steady increase in 2-year survival from 27.8% to 54.8% even as patient age at the time of relapse after allogeneic hematopoietic stem cell transplantation (HCST) increased.

A new retrospective analysis proposes cutoff values that could help physicians identify patients at highest risk of severe kidney complications.

The first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years launched in the United States in November 2021 after being approved in August 2020.

A meta-analysis found an association between Kawasaki disease and subsequent asthma and allergic rhinitis.

For patients with multiple myeloma (MM) who are not eligible for transplant, should novel treatments be used right away? Or should clinicians save the best potential therapies for relapses, which are inevitable with this disease?

Robert Groves, MD, and Bhavesh Shah, PharmD, comment on the role real-world evidence plays in creating cost/value analyses for psoriasis and metabolic syndrome.

Dr Groves discusses the impact of population health knowledge in patients with metabolic syndrome.

Daridorexant belongs to a class of drugs known as a dual orexin receptor antagonists.

A combination of onabotulinumtoxinA and a calcitonin gene-related peptide monoclonal antibody appears effective and safe in patients with chronic migraine, according to real-world data.

New evidence suggests macrophage regulation could be an important area of inquiry in systemic lupus erythematosus, but the research is in its early stages.

Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.

Graft-versus-host disease (GVHD) is common, yet it is poorly understood and its symptoms can be difficult to recognize.

Minimal residual disease (MRD) can predict which patients with classical Hodgkin lymphoma (HL) will relapse after autologous stem cell transplantation (ASCT).

Based on the data from over 5000 patients with spinal muscular atrophy (SMA) and 50,000 age-matched controls, patients with SMA had a nearly 1.8-fold higher mortality rate.

One-year outcomes varied among patients with differing neovascular glaucoma etiologies, but many achieved meaningful vision after surgical treatment that included glaucoma drainage devices.

The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.

The new study suggests certain sub-categories of patients are at particularly high risk.

Researchers raise questions on rapid tests' accuracy early in COVID-19 infection; data show dementia prevalence could triple by 2050; COVID-19 vaccines could lead to minor, temporary changes in menstruation cycles.

The researchers found that even with low amounts or no amount of neutrophils present in the peripheral blood, patients still exhibited active disease.

Human papillomavirus surrogate marker p16 was identified as a potential prognostic biomarker for standard-of-care immune checkpoint blockade therapy response in non-oropharyngeal head and neck squamous cell carcinoma.

Authors described recent therapeutic developments in heart failure with preserved ejection fraction (HFpEF) and proposed a conceptual framework for more targeted treatment.